Cancer Center Support (CORE) Grant

描述（由申请人提供）：德克萨斯大学MD安德森癌症中心是德克萨斯大学系统内的一个独立的综合性癌症中心。2011年，该机构庆祝了其成立70周年，并欢迎罗纳德·德皮尼奥（Ronald DePinho）博士担任CCSG的第四任全职总裁和PI。MD安德森癌症中心的使命是通过卓越的患者护理、研究、教育和预防综合项目，在德克萨斯州、全国乃至全世界消除癌症。MD安德森癌症中心完全致力于癌症研究，包括基础、临床和基于人群的连续调查，重点是多学科转化研究。在过去的5年里，癌症中心成员的数量增加了14%，包括正在建设的设施增加了56%，每年新患者增加到34000人。2011年，Web of Science的年度引用量增加到2507次（16.5%），其中包括283篇影响因子为bb10的期刊文章，反映了对癌症研究的重大贡献。研究预算总额增加了40%，从4.45亿美元增加到6.24亿美元。NCI的拨款支持从1.15亿美元增加到1.2亿美元（3%），其中NCI的拨款数量是所有中心中最多的，包括11个孢子和13个P01s。研究项目保持在19个，并要求为16个共享资源提供支持。自上次CCSG更新以来，基础科学得到了大幅加强，招募了免疫学，基因组学，蛋白质组学，药物发现和癌症生物学方面的世界级领导者。在这十年中，通过MD安德森在癌症治疗连续体上的“登月”努力，转化研究得到了加强，战略规划得到了实施，以加速癌症死亡的减少。这些规划工作是由CCSG疾病项目及其建立的多学科互动实现的。自上次更新以来，MD安德森开发的21种新药已进入临床试验，预计接下来将有8种新药进入临床试验

DESCRIPTION (provided by applicant): The University of Texas MD Anderson Cancer Center is a free-standing comprehensive cancer center within the University of Texas system. In 2011, the institution marked its 70th anniversary and it welcomed Ronald DePinho, M.D., as its fourth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 14%, facilities including those under construction have increased 56% and new patients have increased to 34,000 annually. Annual citations in Web of Science have increased to 2507 in 2011 (16.5%), including 283 articles in journals with an impact factor >10, reflecting substantial contributions to cancer research. The total research budget increased 40% from $445 million to $624 million. NCI grant support has increased from $115M to $120M (3%) with the largest number of NCI grants for any center (>220), including 11 SPOREs and 13 P01s. Research Programs remain at 19 and support is requested for 16 shared resources. Since the last CCSG renewal, basic science has been strengthened substantially with recruitment of world class leaders in immunology, genomics, proteomics, drug discovery and cancer biology. Translational research has been enhanced and strategic planning implemented to accelerate reductions in cancer deaths in this decade, through MD Anderson's 'moon shot' efforts across the cancer care continuum focused on several major cancers. These planning efforts were made possible by the CCSG disease programs and their well-established multi-disciplinary interactions. Since the last renewal 21 new agents developed at MD Anderson have entered clinical trials, 8 additional agents are expected to enter clinical trials in the next year and 12 INDs were prepared by the cancer center. Clinical research has been strengthened with new leadership, further development of infrastructure and data bases, and emphasis on hypothesis driven, investigator initiated trials. Cancer is a global problem, and MD Anderson has built a network of 26 Sister Institutions in 19 countries to facilitate research and educational activities. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide.